Human chorionic gonadotropin (HCG) is a polypeptide hormone produced by cells formed in trophoblastic tissue of the developing embryo soon after conception. It induces and supports the development and maintenance of corpus luteum throughout early stages of pregnancy. HCG is used medically to induce ovulation and pregnancy in certain infertility treatments. It can be produced and administered by injection or vaginal use to induce or maintain pregnancy. The medical applications of HCG mainly includes fertility treatments, cancer screening and treatments. The global Human Chorionic Gonadotropin (HCG) Market is estimated to be valued at US$ 710.88 Mn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Wide range of medical applications presents a major market opportunity for the HCG market over the forecast period. HCG has applications in fertility industry where it is used in ovulation induction and assisted reproductive technology treatments such as in vitro fertilization. In cancer, it plays an important role in cancer screening and treatment monitoring. HCG is produced by certain cancers such as trophoblastic tumors, testicular cancer and ovarian cancer. Measurement of HCG levels helps in early detection of such cancers. During chemotherapy treatment of germ cell tumors, HCG levels are monitored to assess the treatment response. For testicular cancer screening and monitoring, HCG blood test forms an essential part of treatment regimen. Thus growing prevalence of cancers and increasing acceptance of assisted reproductive technologies worldwide provide impetus to the HCG market growth over the forecast period.
Porter's Analysis
Threat of new entrants: The HCG market is moderately difficult to enter due to requirements for specialized production facilities and strict regulatory approvals. However, growth opportunities exist for biosimilar and generic versions.
Bargaining power of buyers: Individual consumers have low bargaining power, while larger healthcare providers and insurers have moderate power due to potential for volume-based negotiations.
Bargaining power of suppliers: A few major suppliers of HCG active pharmaceutical ingredients control a significant share, exerting pricing pressure on drug developers.
Threat of new substitutes: No close substitutes exist for HCG used in fertility treatment and weight loss. Research into alternative hormones remains at an early stage.
Competitive rivalry: The market features many global and regional players. Competition is based on product quality, reliability of supply, price, and marketing.
SWOT Analysis
Strengths: Well-established use of HCG in fertility and weight loss. Growing awareness and demand in developing nations.
Weaknesses: Requires injection/home administration, potential side effects. Raw material supply dependent on few major players.
Opportunities: Untapped growth potential in Asia Pacific and Latin America. Development of longer-acting formulations and delivery methods.
Threats: Stringent regulatory norms. Threat from generic competition once patents expire on major brands. Emergence of alternative treatment options.
Key Takeaways
The global HCG market is expected to witness high growth over the forecast period of 2023-2030 supported by increasing fertility rates worldwide and growth of the medical tourism industry.
Regional analysis: North America commands the largest share of the HCG market due to well-established healthcare infrastructure and growing medical tourism. However, Asia Pacific is expected to grow at the fastest pace due to large patient population, rising medical standards, and growing medical tourism in countries like India and Thailand.
Key players analysis: Key players operating in the HCG market are Merck & Co., Inc., Ferring B.V.,Fresenius SE & Co.KGaA,Lupin,Sun Pharmaceutical Industries Ltd,Lee BioSolutions,Serum Institute of India Pvt. Ltd., Scripps Laboratories,Sanzyme Biologics Pvt. Ltd.,VHB Medi Sciences Limited, Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd. These players are focusing on new product launches, collaborations and geographic expansions to remain competitive.
